Alumis (ALMS)
Develops oral TYK2 therapies for immune-mediated diseases in the body and brain.
$7.37
vs last close−0.74 (−9.12%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 90.91% | 117.67M shares | |
|---|---|---|---|
| 213 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.32% | 1.71M shares | |
| 15 holders · as of Sep 9, 2026 | |||
| Strategic holders | 0.53% | 680.5K shares | |
| 1 holder · as of Apr 3, 2026 | |||
| Other | ≈ 7.24% | 9.38M shares | |
| remainder | |||
129.44M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
213 holders · 117.67M shares · 32 new positions · 108 increased · 64 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ayurmaya Capital Management Company, LP | 15.14M | 11.70% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 8.22M | 6.35% | +1.05M | Aug 7, 2026 |
| FMR LLC | 6.77M | 5.23% | +5.80M | Aug 13, 2026 |
| Deep Track Capital, LP | 6.35M | 4.90% | −424.0K | Aug 14, 2026 |
| Samsara Biocapital, LLC | 6.35M | 4.90% | 0 | Aug 14, 2026 |
| Foresite Capital Management V, LLC | 5.90M | 4.56% | 0 | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 5.20M | 4.02% | +1.91M | Aug 14, 2026 |
| Venbio Partners LLC | 4.53M | 3.50% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| James B. Tananbaumincl. Foresite Capital Opportunity Management V, LLC, Foresite Capital Fund VI LP +4 more | 14.50% | 9.18M | 13D | Aug 17, 2026 |
| AyurMaya Capital Management Company, LPincl. David E. Goel | 12.30% | 15.14M | 13D | Jul 2, 2026 |
| Deep Track Capital, LP | 5.98% | 7.36M | 13G | Apr 7, 2026 |
| BlackRock, Inc. | 5.70% | 7.07M | 13G | Jul 27, 2026 |
| Srinivas Akkarajuincl. Samsara Opportunity Fund, L.P., Samsara BioCapital GP, LLC +2 more | 5.40% | 6.35M | 13D | Jan 13, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 8, 2026 | Srinivas Akkarajudirector | Purchase · 2 lots | 546,581 | $10.63 | 4,937,026 |
| Sep 8, 2026 | Srinivas Akkarajudirector | Sale · 2 lots | 96,131 | $10.55 | 2,025,493 |
| Sep 4, 2026 | Srinivas Akkarajudirector | Purchase | 220,070 | $11.17 | 4,711,801 |
| Aug 3, 2026 | Mark Christopher Bradleyofficer: Chief Development Officer | Sale | 2,572 | $26.37 | 48,533 |
| Aug 3, 2026 | Jorn Drappaofficer: Chief Medical Officer | Sale | 2,447 | $26.37 | 56,892 |
| Aug 3, 2026 | David M. Goldsteinofficer: Chief Scientific Officer | Sale | 2,596 | $26.37 | 30,970 |
| Aug 3, 2026 | Roy C. Hardimanofficer: Chief Business & Strategy Ofcr | Sale | 2,692 | $26.37 | 207,746 |
| Aug 3, 2026 | Sanam Pangaliofficer: Chief Legal Officer | Sale | 1,364 | $26.37 | 9,747 |
| Aug 3, 2026 | John R. Schroerofficer: Chief Financial Officer | Sale | 3,282 | $26.37 | 24,718 |
| Jul 6, 2026 | Sanam Pangaliofficer: Chief Legal Officer | Sale | 5,000 | $28.00 | 11,111 |
House and Senate disclosures
Not reported.